

# The Nord-Trondelag Health Study

<https://www.neurodegenerationresearch.eu/survey/the-nord-trondelag-health-study/>

## Title of the cohort

The Nord-Trondelag Health Study

## Acronym for cohort

HUNT

## Name of Principal Investigator

Title Professor

First name Kristian

Last name Hveem

## Address of institution where award is held

Institution HUNT Research Centre

Street Address Forskningsveien 2

City Levanger

Postcode NO-7600

## Country

- Norway

## Website

<http://www.ntnu.edu/hunt/inenglish>

## Contact email

[email protected]

## Funding source

The Research Council of Norway and others.

## 1. The cohort includes, or expects to include, incidence of the following conditions

- Neurodegenerative disease in general

## When studies on the above condition(s) are expected to become possible

- Already possible

## 2a. Stated aim of the cohort

The fundamental strategy is to earn and maintain the confidence of the population we work in and with as is necessary for any successful population study.

## **2b. Features distinguishing this cohort from other population cohorts**

### **3a. i) Number of publications that involve use of cohort to date**

Yes. <http://www.ntnu.edu/hunt>

### **3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**

<http://www.ntnu.no/hunt/sok>

### **3b. Publication list/link to where data or publications are accessible (if available)**

<http://www.ntnu.no/hunt/sok>

### **3c. Information (i.e. research findings) expected to be gained from the population cohort**

#### **4a. Study criteria: age range of participants at recruitment**

Age in years from: 13

To ('until death' if applicable): 100

#### **4b. Study criteria: inclusion criteria**

Population based.

#### **4c. Study criteria: exclusion criteria**

Polulation based.

### **5. Size of the cohort (i.e. number of participants enrolled)**

- More than 15,000

### **6a. Measures used to characterise participants**

<http://www.ntnu.edu/hunt/inenglish>

### **6b. Additional measures for participants with a clinical disorder**

### **6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

<http://www.ntnu.edu/hunt/inenglish>

## **7. Study design**

- Cross sectional survey

## **8. Cases matched by**

- Age
- Sex
- Co-morbidities

- Cognitive function
- Physical ability
- Other health assessment (specify) / N/A
- From question

**9a. Does the study include a specialised subset of control participants**

- Yes

**9b. If yes, description of specialised subset of control participants**

population based

**10a. i) Data collection start date**

01-03-2011

**10a. ii) Data collection end date**

01-03-2011

**10a iii) Data collection for this study is**

- Data collection ongoing
- Data analysis ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**

**11. Data collected**

- Through links to medical records
- Through links to other records or registers (such as dental records, police records etc). Please specify
- <http://www.ntnu.edu/hunt>

**12. System in place to enable re-contact with patients for future studies**

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**

Language used:

**13b. Format and availability of data held as individual records**

Language used:

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- National access
- International access

- Access independent of collaboration with PI
- Access Committee mechanism
- Applicant needs to provide separate external ethics approval

**15. Data sharing policy specified as a condition of use**

- No requirement to make data publicly available

**16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors: blood
- Living donors: DNA

**16b. ii) Form available tissues/samples/DNA are supplied in**

- Primary samples: Supplied fresh
- Secondary samples: DNA

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

Yes

**17. Is information on biological characteristics available to other groups**

- Yes, for all the cohort